Verve focused on breakthrough gene-editing approaches to cardiovascular disease rather than traditional pharma models, positioning itself at the frontier of genetic medicine. The company achieved key regulatory milestones, receiving FDA Fast Track designation for VERVE-102 in April 2025, before its acquisition by Eli Lilly.
Cyborg Score Rationale
The company demonstrated promising scientific innovation and regulatory momentum, but faced substantial clinical and financial headwinds as a pre-revenue biotech. Analyst consensus was Hold as of February 2026, reflecting uncertainty about clinical advancement and profitability.
Top Insights
Achieved FDA Fast Track designation for VERVE-102 in April 2025, signaling regulatory confidence in the lead program
Projected net loss of $2.38 per share for 2025, with no revenue generation and early-stage pipeline
Limited catalysts prior to acquisition, raising concerns about ability to advance candidates through clinical development
Acquired by Eli Lilly in July 2025 at $14.57 per share, validating the genetic medicine approach but ending independent operations
Named Competitors
CRISPR — Gene-editing therapeutics using CRISPR technology
Beam — Precision genetic medicines via base editing
Prime Medicine — Prime editing platform for genetic medicine
Repatha — PCSK9 inhibitor for cardiovascular disease
Recent Developments
(April 2025) VERVE-102 received FDA Fast Track designation for PCSK9 targeting cardiovascular disease
(July 2025) Acquisition by Eli Lilly and Company completed; stock delisted from Nasdaq
(February 2026) Analyst consensus rating was Hold with price target of $14.57 per share
Open the full interactive Verve Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.